News Related to Duality Bio

Related coverage linked through entity extraction aliases.

BioNTech Faces Mixed Analyst Views, FDA Fast-Track Designation, and Leadership Transition

May 26, 2026

BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.

BioNTech heads into May with earnings, shareholder vote and oncology pipeline focus

Apr 25, 2026

BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.